Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
The insider still has significant holdings in the company, signaling confidence.
Overview
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($49.23); post-transaction value based on Aug. 17, 2026, market close ($49.85).
Details
Alkermes is a Dublin-headquartered biopharmaceutical company with a market capitalization of $7.9 billion and TTM revenues of $1.7 billion, positioning it as a significant player in the neuropsychiatric therapeutics space. The company maintains a diversified portfolio of commercial products and clinical-stage candidates, with a strategic focus on addressing high-prevalence conditions including opioid dependence, alcohol use disorder, and schizophrenia. Alkermes' competitive differentiation is anchored in its proprietary drug delivery technologies and sustained focus on underserved patient populations in mental health and addiction medicine.
Source
Originally published at www.fool.com.